Cited by 234Ovarian cancer diagnosis and treatmentCancer Cells and MetastasisCancer Mechanisms and Therapy

The DOI matches its Crossref record; 47 of the 49 references it cites were found in a registry or an index.

AXL Is an Essential Factor and Therapeutic Target for Metastatic Ovarian Cancer

Open access

Rankin, Erinn B., Fuh, Katherine C., Taylor, Tiffany E., Krieg, Adam J., Musser, Margaret, Yuan, Jenny, Wei, Kevin, Kuo, Calvin J., Longacre, Teri A., Giaccia, Amato J.·2010·Cancer Research

DOI 10.1158/0008-5472.can-10-1267PMC PMC3408227

Published version of a preprint

Open this paper in CoChat — free account Open PDF

Abstract

The receptor tyrosine kinase AXL is thought to play a role in metastasis; however, the therapeutic efficacy of an AXL-targeting agent remains largely untested in metastatic disease. In this study, we defined AXL as a therapeutic target for metastatic ovarian cancer. AXL is primarily expressed in metastases and advanced-stage human ovarian tumors but not in normal ovarian epithelium. Genetic inhibition of AXL in human metastatic ovarian tumor cells is sufficient to prevent the initiation of metastatic disease in vivo. Mechanistically, inhibition of AXL signaling in animals with metastatic disease results in decreased invasion and matrix metalloproteinase activity. Most importantly, soluble human AXL receptors that imposed a specific blockade of the GAS6/AXL pathway had a profound inhibitory effect on progression of established metastatic ovarian cancer without normal tissue toxicity. These results offer the first genetic validation of GAS6/AXL targeting as an effective strategy for inhibition of metastatic tumor progression in vivo. Furthermore, this study defines the soluble AXL receptor as a therapeutic candidate agent for treatment of metastatic ovarian cancer, for which current therapies are ineffective. Cancer Res; 70(19); 7570–9. ©2010 AACR.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1158/0008-5472.can-10-1267

Cites

47 of 47 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

1 retracted

RETRACTED ARTICLE: Soluble Axl Is Generated by ADAM10-Dependent Cleavage and Associates with Gas6 in Mouse Serum
Budagian, V., Bulanova, E., Orinska, Z., Duitman, E. H., Brandt, K., Ludwig, A., Hartmann, D., Lemke, G., Säftig, P., & Bulfone‐Paus, S. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.21.9324-9339.2005 · Cited by 84
Retracted
New functions for the matrix metalloproteinases in cancer progression
Egeblad, M., & Werb, Z. (2002) · Nature Reviews Cancer · doi:10.1038/nrc745 · Cited by 6,108
Matrix Metalloproteinase Inhibitors and Cancer—Trials and Tribulations
Coussens, L. M., Fingleton, B., & Matrisian, L. M. (2002) · Science · doi:10.1126/science.1067100 · Cited by 2,761
The Origin and Pathogenesis of Epithelial Ovarian Cancer: A Proposed Unifying Theory
Kurman, R. J., & Shih, I. (2010) · The American Journal of Surgical Pathology · doi:10.1097/pas.0b013e3181cf3d79 · Cited by 1,890
Tumor Self-Seeding by Circulating Cancer Cells
Kim, M.-Y., Oskarsson, T., Acharyya, S., Nguyen, D. X., Zhang, X. H.-F., Norton, L., & Massagué, J. (2009) · Cell · doi:10.1016/j.cell.2009.11.025 · Cited by 1,335
TAM Receptor Tyrosine Kinases: Biologic Functions, Signaling, and Potential Therapeutic Targeting in Human Cancer
Linger, R. M. A., Keating, A. K., Earp, H. S., & Graham, D. K. (2008) · Advances in cancer research · doi:10.1016/s0065-230x(08)00002-x · Cited by 750
axl, a transforming gene isolated from primary human myeloid leukemia cells, encodes a novel receptor tyrosine kinase.
O’Bryan, J. P., Frye, R. A., Cogswell, P. C., Neubauer, A., Kitch, B., Prokop, C. A., Espinosa, R., Beau, M. M. L., Earp, H. S., & Liu, E. (1991) · Molecular and Cellular Biology · doi:10.1128/mcb.11.10.5016 · Cited by 746
Homeostatic Regulation of the Immune System by Receptor Tyrosine Kinases of the Tyro 3 Family
Lu, Q., & Lemke, G. (2001) · Science · doi:10.1126/science.1061663 · Cited by 699
Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival
Gjerdrum, C., Tiron, C., Høiby, T., Stefansson, I., Haugen, H., Sandal, T., Collett, K., Li, S., McCormack, E., Gjertsen, B. T., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0909333107 · Cited by 594
R428, a Selective Small Molecule Inhibitor of Axl Kinase, Blocks Tumor Spread and Prolongs Survival in Models of Metastatic Breast Cancer
Holland, S. J., Pan, A., Franci, C., Hu, Y., Chang, B. Y., Li, W., Duan, M., Torneros, A., Yu, J., Heckrodt, T. J., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-2997 · Cited by 567

Show all 49 references

Sorted by citations

Hypoxic control of metastasis
Rankin, E. B., & Giaccia, A. J. (2016) · Science · doi:10.1126/science.aaf4405 · Cited by 1,340
Self-citation
Biomarkers for the early diagnosis of hepatocellular carcinoma
Tsuchiya, N. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i37.10573 · Cited by 571
AXL receptor tyrosine kinase as a promising anti-cancer approach: functions, molecular mechanisms and clinical applications
Zhu, C., Wei, Y., & Wei, X. (2019) · Molecular Cancer · doi:10.1186/s12943-019-1090-3 · Cited by 507
Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma
Zhou, L., Liu, X.-D., Sun, M., Zhang, X., German, P., Bai, S., Ding, Z., Tannir, N. M., Wood, C. G., Matin, S. F., et al. (2015) · Oncogene · doi:10.1038/onc.2015.343 · Cited by 400
Self-citation
AXL induces epithelial-to-mesenchymal transition and regulates the function of breast cancer stem cells
Asiedu, M. K., Beauchamp‐Perez, F., Ingle, J. N., Behrens, M. D., Radisky, D. C., & Knutson, K. L. (2013) · Oncogene · doi:10.1038/onc.2013.57 · Cited by 302
Direct regulation of GAS6/AXL signaling by HIF promotes renal metastasis through SRC and MET
Rankin, E. B., Fuh, K. C., Castellini, L., Viswanathan, K., Finger, E. C., Diep, A. N., LaGory, E. L., Kariolis, M. S., Chan, A., Lindgren, D., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1404848111 · Cited by 269
Self-citation
Targeting Axl and Mer Kinases in Cancer
Verma, A. R., Warner, S. L., Vankayalapati, H., Bearss, D. J., & Sharma, S. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0116 · Cited by 226
AXL Mediates Resistance to Cetuximab Therapy
Brand, T. M., Iida, M., Stein, A. P., Corrigan, K. L., Braverman, C. M., Luthar, N., Toulany, M., Gill, P. S., Salgia, R., Kimple, R. J., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0294 · Cited by 198
AXL kinase as a novel target for cancer therapy
Wu, X., Liu, X., Koul, S., Lee, C. Y., Zhang, Z., & Halmos, B. (2014) · Oncotarget · doi:10.18632/oncotarget.2542 · Cited by 191
METTL3 promotes ovarian carcinoma growth and invasion through the regulation of AXL translation and epithelial to mesenchymal transition
Hua, W., Zhao, Y., Jin, X., Yu, D., He, J., Xie, D., & Duan, P. (2018) · Gynecologic Oncology · doi:10.1016/j.ygyno.2018.09.015 · Cited by 193
Axl as a mediator of cellular growth and survival
Axelrod, H. D., & Pienta, K. J. (2014) · Oncotarget · doi:10.18632/oncotarget.2422 · Cited by 195
AXL-Driven EMT State as a Targetable Conduit in Cancer
Antony, J., & Huang, R. Y. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-0392 · Cited by 182
The Receptor Tyrosine Kinase AXL in Cancer Progression
Rankin, E. B., & Giaccia, A. J. (2016) · Cancers · doi:10.3390/cancers8110103 · Cited by 174
Self-citation
Receptor tyrosine kinase Axl is required for resistance of leukemic cells to FLT3-targeted therapy in acute myeloid leukemia
Park, I.-K., Mundy-Bosse, B. L., Whitman, S. P., Zhang, X., Warner, S. L., Bearss, D. J., Blum, W. G., Marcucci, G., & Caligiuri, M. A. (2015) · Leukemia · doi:10.1038/leu.2015.147 · Cited by 169
The receptor tyrosine kinase Axl in cancer: Biological functions and therapeutic implications
Paccez, J. D., Vogelsang, M., Parker, M. I., & Zerbini, L. F. (2013) · International Journal of Cancer · doi:10.1002/ijc.28246 · Cited by 151
The Receptor Tyrosine Kinase AXL Is Required at Multiple Steps of the Metastatic Cascade during HER2-Positive Breast Cancer Progression
Goyette, M.-A., Duhamel, S., Aubert, L., Pelletier, A., Savage, P., Thibault, M.-P., Johnson, R. M., Carmeliet, P., Basik, M., Gaboury, L. A., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.04.019 · Cited by 148
An engineered Axl 'decoy receptor' effectively silences the Gas6-Axl signaling axis
Kariolis, M. S., Miao, Y. R., Jones, D. S., Kapur, S., Mathews, I. I., Giaccia, A. J., & Cochran, J. R. (2014) · Nature Chemical Biology · doi:10.1038/nchembio.1636 · Cited by 143
Self-citation
The receptor tyrosine kinase Axl is an essential regulator of prostate cancer proliferation and tumor growth and represents a new therapeutic target
Paccez, J. D., Vasques, G. J., Correa, R. G., de Vasconcellos, J. F., Duncan, K., Gu, X., Bhasin, M., Libermann, T. A., & Zerbini, L. F. (2012) · Oncogene · doi:10.1038/onc.2012.89 · Cited by 141
GAS6 Receptor Status Is Associated with Dormancy and Bone Metastatic Tumor Formation
Taichman, R. S., Patel, L. R., Bedenis, R., Wang, J., Weidner, S., Schumann, T., Yumoto, K., Berry, J. E., Shiozawa, Y., & Pienta, K. J. (2013) · PLoS ONE · doi:10.1371/journal.pone.0061873 · Cited by 133
Ultrasensitive tumour-penetrating nanosensors of protease activity
Kwon, E. J., Dudani, J. S., & Bhatia, S. N. (2017) · Nature Biomedical Engineering · doi:10.1038/s41551-017-0054 · Cited by 131
Molecular Pathways: AXL, a Membrane Receptor Mediator of Resistance to Therapy
Scaltriti, M., Elkabets, M., & Baselga, J. M. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1458 · Cited by 126
Molecular Pathways: Receptor Ectodomain Shedding in Treatment, Resistance, and Monitoring of Cancer
Miller, M. A., Sullivan, R. J., & Lauffenburger, D. A. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0869 · Cited by 128
The HIF target MAFF promotes tumor invasion and metastasis through IL11 and STAT3 signaling
Moon, E. J., Mello, S. S., Li, C. G., Chi, J., Thakkar, K. N., Kirkland, J. G., LaGory, E. L., Lee, I. J., Diep, A. N., Miao, Y. R., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24631-6 · Cited by 130
Self-citation
AXL Is a Logical Molecular Target in Head and Neck Squamous Cell Carcinoma
Brand, T. M., Iida, M., Stein, A. P., Corrigan, K. L., Braverman, C. M., Coan, J. P., Pearson, H. E., Bahrar, H., Fowler, T. L., Bednarz, B. P., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2648 · Cited by 119
ONO-7475, a Novel AXL Inhibitor, Suppresses the Adaptive Resistance to Initial EGFR-TKI Treatment in EGFR -Mutated Non–Small Cell Lung Cancer
Okura, N., Nishioka, N., Yamada, T., Taniguchi, H., Tanimura, K., Katayama, Y., Yoshimura, A., Watanabe, S., Kikuchi, T., Shiotsu, S., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2321 · Cited by 123
Fra-1 controls motility of bladder cancer cells via transcriptional upregulation of the receptor tyrosine kinase AXL
Sayan, E., Stanford, R., Vickery, R., Grigorenko, E. V., Diesch, J., Kulbicki, K., Edwards, R., Pal, R., Greaves, P., Jariel‐Encontre, I., et al. (2011) · Oncogene · doi:10.1038/onc.2011.336 · Cited by 123
The GAS6-AXL signaling network is a mesenchymal (Mes) molecular subtype–specific therapeutic target for ovarian cancer
Antony, J., Tan, T. Z., Kelly, Z. L., Low, J. J. H., Choolani, M. A., Recchi, C., Gabra, H., Thiery, J. P., & Huang, R. Y. (2016) · Science Signaling · doi:10.1126/scisignal.aaf8175 · Cited by 118
Inhibition of the GAS6/AXL pathway augments the efficacy of chemotherapies
Kariolis, M. S., Miao, Y. R., Diep, A. N., Nash, S. E., Olcina, M. M., Jiang, D., Jones, D. S., Kapur, S., Mathews, I. I., Koong, A. C., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci85610 · Cited by 108
Self-citation
Gas6/Axl mediates tumor cell apoptosis, migration and invasion and predicts the clinical outcome of osteosarcoma patients
Han, J., Tian, R., Yong, B., Luo, C., Tan, P., Shen, J., & Peng, T. (2013) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2013.05.019 · Cited by 109
Inhibition of the receptor tyrosine kinase Axl impedes activation of the FLT3 internal tandem duplication in human acute myeloid leukemia: implications for Axl as a potential therapeutic target
Park, I., Mishra, A., Chandler, J. C., Whitman, S. P., Marcucci, G., & Caligiuri, M. A. (2013) · Blood · doi:10.1182/blood-2012-07-444018 · Cited by 109
Preclinical validation of AXL receptor as a target for antibody-based pancreatic cancer immunotherapy
Leconet, W., Larbouret, C., Chardès, T., Thomas, G., Neiveyans, M., Busson, M., Jarlier, M., Radosevic‐Robin, N., Pugnière, M., Bernex, F., et al. (2013) · Oncogene · doi:10.1038/onc.2013.487 · Cited by 107
Axl-EGFR receptor tyrosine kinase hetero-interaction provides EGFR with access to pro-invasive signalling in cancer cells
Vouri, M., Croucher, D. R., Kennedy, S. P., An, Q., Pilkington, G. J., & Hafizi, S. (2016) · Oncogenesis · doi:10.1038/oncsis.2016.66 · Cited by 106
Activation of TYRO3/AXL Tyrosine Kinase Receptors in Thyroid Cancer
Avilla, E., Guarino, V., Visciano, C., Liotti, F., Svelto, M., Krishnamoorthy, G., Franco, R., & Melillo, R. M. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2186 · Cited by 103
The GAS6-AXL signaling pathway triggers actin remodeling that drives membrane ruffling, macropinocytosis, and cancer-cell invasion
Zdżalik-Bielecka, D., Poświata, A., Kozik, K., Jastrzębski, K., Schink, K. O., Brewińska‐Olchowik, M., Piwocka, K., Stenmark, H., & Miączyńska, M. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2024596118 · Cited by 103
Migration/Invasion of Malignant Gliomas and Implications for Therapeutic Treatment
Liu, C.-A., Chang, C., Hsueh, K.-W., Su, H.-L., Chiou, T., Lin, S., & Harn, H. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19041115 · Cited by 104
Axl inhibition induces the antitumor immune response which can be further potentiated by PD-1 blockade in the mouse cancer models
Guo, Z., Li, Y., Zhang, D., & Ma, J. (2017) · Oncotarget · doi:10.18632/oncotarget.21125 · Cited by 103
TAM family kinases as therapeutic targets at the interface of cancer and immunity
DeRyckere, D., Huelse, J. M., Earp, H. S., & Graham, D. K. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00813-7 · Cited by 99
Therapeutic Targeting of the Gas6/Axl Signaling Pathway in Cancer
Tanaka, M., & Siemann, D. W. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22189953 · Cited by 94
Pyruvate uptake is increased in highly invasive ovarian cancer cells under anoikis conditions for anaplerosis, mitochondrial function, and migration
Caneba, C. A., Bellancé, N., Yang, L., Pabst, L., & Nagrath, D. (2012) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00151.2012 · Cited by 99
The EZH2 inhibitor GSK343 suppresses cancer stem-like phenotypes and reverses mesenchymal transition in glioma cells
Yu, T., Wang, Y., Hu, Q., Wu, W., Wu, Y., Wei, W., Han, D., You, Y., Lin, N., & Liu, N. (2017) · Oncotarget · doi:10.18632/oncotarget.21311 · Cited by 99
AXL signaling in cancer: from molecular insights to targeted therapies
Yadav, M., Sharma, A., Patne, K., Tabasum, S., Suryavanshi, J., Rawat, L., Machaalani, M., Eid, M., Singh, R. P., Choueiri, T. K., et al. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02121-7 · Cited by 99
The Role of the Receptor Tyrosine Kinase Axl in Carcinogenesis and Development of Therapeutic Resistance: An Overview of Molecular Mechanisms and Future Applications
Wium, M., Ajayi-Smith, A. F., Paccez, J. D., & Zerbini, L. F. (2021) · Cancers · doi:10.3390/cancers13071521 · Cited by 81
Polarization of tumor-associated macrophages and Gas6/Axl signaling in oral squamous cell carcinoma
Chiu, K., Lee, C.-H., Liu, S.-Y., Chou, Y., Huang, R., Huang, S., & Shieh, Y. (2015) · Oral Oncology · doi:10.1016/j.oraloncology.2015.04.004 · Cited by 81
AXL Receptor Tyrosine Kinase as a Promising Therapeutic Target Directing Multiple Aspects of Cancer Progression and Metastasis
Goyette, M.-A., & Côté, J. (2022) · Cancers · doi:10.3390/cancers14030466 · Cited by 80
Therapeutic targeting of the functionally elusive TAM receptor family
Miao, Y. R., Rankin, E. B., & Giaccia, A. J. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00846-8 · Cited by 88
Self-citation
Therapeutic Targeting of AXL Receptor Tyrosine Kinase Inhibits Tumor Growth and Intraperitoneal Metastasis in Ovarian Cancer Models
Kanlikilicer, P., Özpolat, B., Aslan, B., Bayraktar, R., Gürbüz, N., Rodriguez‐Aguayo, C., Bayraktar, E., Denizli, M., González-Villasana, V., Ivan, C., et al. (2017) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2017.06.023 · Cited by 77
Homing of Cancer Cells to the Bone
Mishra, A., Shiozawa, Y., Pienta, K. J., & Taichman, R. S. (2011) · Cancer Microenvironment · doi:10.1007/s12307-011-0083-6 · Cited by 76
TWIST1 drives cisplatin resistance and cell survival in an ovarian cancer model, via upregulation of GAS6, L1CAM, and Akt signalling
Roberts, C. M., Tran, M. A., Pitruzzello, M. C., Wen, W. X., Loeza, J., Dellinger, T. H., Mor, G., & Glackin, C. A. (2016) · Scientific Reports · doi:10.1038/srep37652 · Cited by 72
Targeted Axl Inhibition Primes Chronic Lymphocytic Leukemia B Cells to Apoptosis and Shows Synergistic/Additive Effects in Combination with BTK Inhibitors
Sinha, S., Boysen, J. C., Nelson, M., Secreto, C. R., Warner, S. L., Bearss, D. J., Lesnick, C. E., Shanafelt, T. D., Kay, N. E., & Ghosh, A. K. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1892 · Cited by 75
Axl inhibitors as novel cancer therapeutic agents
Shen, Y., Chen, X., He, J., Liao, D., & Zu, X. (2018) · Life Sciences · doi:10.1016/j.lfs.2018.02.033 · Cited by 72
Cancer stem-like cells enriched with CD29 and CD44 markers exhibit molecular characteristics with epithelial–mesenchymal transition in squamous cell carcinoma
Geng, S., Guo, Y., Wang, Q., Li, L., & Wang, J. (2012) · Archives of Dermatological Research · doi:10.1007/s00403-012-1260-2 · Cited by 72
The Dual Role of TAM Receptors in Autoimmune Diseases and Cancer: An Overview
Wium, M., Paccez, J. D., & Zerbini, L. F. (2018) · Cells · doi:10.3390/cells7100166 · Cited by 73
Epithelial-to-mesenchymal transition: lessons from development, insights into cancer and the potential of EMT-subtype based therapeutic intervention
Antony, J., Thiery, J. P., & Huang, R. Y. (2019) · Physical Biology · doi:10.1088/1478-3975/ab157a · Cited by 70
Treatment of Ovarian Cancer Beyond PARP Inhibition: Current and Future Options
Garg, V., & Oza, A. M. (2023) · Drugs · doi:10.1007/s40265-023-01934-0 · Cited by 71
Global phosphotyrosine survey in triple-negative breast cancer reveals activation of multiple tyrosine kinase signaling pathways
Wu, X., Zahari, M. S., Ma, B., Liu, R., Renuse, S., Sahasrabuddhe, N. A., Chen, L., Chaerkady, R., Kim, M., Zhong, J., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.5020 · Cited by 66
MERTK Mediates Intrinsic and Adaptive Resistance to AXL-targeting Agents
McDaniel, N. K., Cummings, C. T., Iida, M., Huelse, J. M., Pearson, H. E., Vasileiadi, E., Parker, R. E., Orbuch, R. A., Ondracek, O. J., Welke, N. B., et al. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-1239 · Cited by 66
Implications of Hypoxia in Breast Cancer Metastasis to Bone
Gilkes, D. M. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17101669 · Cited by 65
Targeting Axl favors an antitumorigenic microenvironment that enhances immunotherapy responses by decreasing Hif-1α levels
Goyette, M.-A., Elkholi, I. E., Apcher, C., Kuasne, H., Rothlin, C. V., Muller, W. J., Richard, D. E., Park, M., Gratton, J., & Côté, J. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2023868118 · Cited by 64
4-Oxo-1,4-dihydroquinoline-3-carboxamide Derivatives as New Axl Kinase Inhibitors
Tan, L., Zhang, Z., Gao, D., Luo, J., Tu, Z., Li, Z., Peng, L., Ren, X., & Ding, K. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00608 · Cited by 61
METTL3 promotes the initiation and metastasis of ovarian cancer by inhibiting CCNG2 expression via promoting the maturation of pri-microRNA-1246
Bi, X., Lv, X., Liu, D. J., Guo, H., Yao, G., Wang, L., Liang, X., & Yang, Y. (2021) · Cell Death Discovery · doi:10.1038/s41420-021-00600-2 · Cited by 62
The histone demethylase KDM4B regulates peritoneal seeding of ovarian cancer
Wilson, C. B., Qiu, L., Hong, Y., Karnik, T., Tadros, G., Mau, B., Ma, T., Mu, Y., New, J., Louie, R. J., et al. (2016) · Oncogene · doi:10.1038/onc.2016.412 · Cited by 61
Self-citation
Erratum to: Cancer stem-like cells enriched with CD29 and CD44 markers exhibit molecular characteristics with epithelial–mesenchymal transition in squamous cell carcinoma
Geng, S., Guo, Y., Wang, Q., Li, L., & Wang, J. (2017) · Archives of Dermatological Research · doi:10.1007/s00403-017-1737-0 · Cited by 59
GAS6 expression identifies high-risk adult AML patients: potential implications for therapy
Whitman, S. P., Kohlschmidt, J., Maharry, K. S., Volinia, S., Mrózek, K., Nicolet, D., Schwind, S., Becker, H., Metzeler, K. H., Mendler, J. H., et al. (2013) · Leukemia · doi:10.1038/leu.2013.371 · Cited by 60
MAPK Activation Predicts Poor Outcome and the MEK Inhibitor, Selumetinib, Reverses Antiestrogen Resistance in ER-Positive High-Grade Serous Ovarian Cancer
Hew, K. E., Miller, P. C., El‐Ashry, D., Sun, J., Besser, A. H., Ince, T. A., Gu, M., Wei, Z., Zhang, G., Brafford, P. A., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0534 · Cited by 58
High expression of CDC6 is associated with accelerated cell proliferation and poor prognosis of epithelial ovarian cancer
Deng, Y., Jiang, L., Wang, Y., Xi, Q., Zhong, J., Liu, J., Yang, S., Liu, R., Wang, J., Huang, M., et al. (2015) · Pathology - Research and Practice · doi:10.1016/j.prp.2015.09.014 · Cited by 56
MERTK controls melanoma cell migration and survival and differentially regulates cell behavior relative to AXL
Tworkoski, K., Platt, J. T., Bacchiocchi, A., Bosenberg, M., Boggon, T. J., & Stern, D. F. (2013) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12110 · Cited by 57
The Development of AXL Inhibitors in Lung Cancer: Recent Progress and Challenges
Sang, Y. B., Kim, J.-H., Kim, C.-G., Hong, M. H., Kim, H. R., Cho, B. C., & Lim, S. M. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.811247 · Cited by 56
Molecular Mechanism of 17-Allylamino-17-demethoxygeldanamycin (17-AAG)-induced AXL Receptor Tyrosine Kinase Degradation
Krishnamoorthy, G. P., Guida, T., Alfano, L., Avilla, E., Santoro, M. M., Carlomagno, F., & Melillo, R. M. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.439422 · Cited by 55
GAS6/AXL Inhibition Enhances Ovarian Cancer Sensitivity to Chemotherapy and PARP Inhibition through Increased DNA Damage and Enhanced Replication Stress
Mullen, M. M., Lomonosova, E., Toboni, M. D., Oplt, A., Cybulla, E., Blachut, B., Zhao, P., Noia, H. M., Wilke, D., Rankin, E. B., et al. (2021) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-21-0302 · Cited by 56
Self-citation
AXL Receptor in Cancer Metastasis and Drug Resistance: When Normal Functions Go Askew
Auyez, A., Sayan, E., Kriajevska, M. V., & Tulchinsky, E. M. (2021) · Cancers · doi:10.3390/cancers13194864 · Cited by 50
Promotion of Glioblastoma Cell Motility by Enhancer of Zeste Homolog 2 (EZH2) Is Mediated by AXL Receptor Kinase
Ott, M., Litzenburger, U. M., Sahm, F., Rauschenbach, K. J., Tudoran, R., Hartmann, C. J., Márquez, V. E., von Deimling, A., Wick, W., & Platten, M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0047663 · Cited by 55
Therapeutic Inhibition of the Receptor Tyrosine Kinase AXL Improves Sensitivity to Platinum and Taxane in Ovarian Cancer
Quinn, J. M., Greenwade, M. M., Palisoul, M. L., Opara, G., Massad, K., Guo, L., Zhao, P., Beck-Noia, H., Hagemann, I. S., Hagemann, A. R., et al. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-0537 · Cited by 52
Self-citation
Curcumin-induced downregulation of Axl receptor tyrosine kinase inhibits cell proliferation and circumvents chemoresistance in non-small lung cancer cells
KIM, K.-C., Baek, S., & Lee, C. (2015) · International Journal of Oncology · doi:10.3892/ijo.2015.3216 · Cited by 51
Small molecule inhibition of Axl receptor tyrosine kinase potently suppresses multiple malignant properties of glioma cells
Vouri, M., An, Q., Birt, M., Pilkington, G. J., & Hafizi, S. (2015) · Oncotarget · doi:10.18632/oncotarget.3952 · Cited by 49
Anticancer effect of luteolin is mediated by downregulation of TAM receptor tyrosine kinases, but not interleukin-8, in non-small cell lung cancer cells
Lee, Y. J., Lim, T., Han, M. S., Lee, S. H., Baek, S., Nan, H., & Lee, C. (2016) · Oncology Reports · doi:10.3892/or.2016.5336 · Cited by 49
Axl signaling is an important mediator of tumor angiogenesis
Tanaka, M., & Siemann, D. W. (2019) · Oncotarget · doi:10.18632/oncotarget.26882 · Cited by 49
Reversal of Cisplatin Resistance by Epigallocatechin Gallate Is Mediated by Downregulation of Axl and Tyro 3 Expression in Human Lung Cancer Cells
Kim, K.-C., & Lee, C. (2014) · Korean Journal of Physiology and Pharmacology · doi:10.4196/kjpp.2014.18.1.61 · Cited by 47
RNA m6A methylation regulators in ovarian cancer
Guo, J., Zheng, J., Zhang, H., & Tong, J. (2021) · Cancer Cell International · doi:10.1186/s12935-021-02318-8 · Cited by 47
Implication of the Receptor Tyrosine Kinase AXL in Head and Neck Cancer Progression
von Mäßenhausen, A., Brägelmann, J., Billig, H., Thewes, B., Queisser, A., Vogel, W., Kristiansen, G., Schröck, A., Bootz, F., Brossart, P., et al. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms18010007 · Cited by 46
Bioinformatics analysis to screen the key prognostic genes in ovarian cancer
Li, L., Cai, S., Liu, S., Feng, H., & Zhang, J. (2017) · Journal of Ovarian Research · doi:10.1186/s13048-017-0323-6 · Cited by 46
Metformin targets Axl and Tyro3 receptor tyrosine kinases to inhibit cell proliferation and overcome chemoresistance in ovarian cancer cells
Kim, N., Lee, H., & Lee, C. (2015) · International Journal of Oncology · doi:10.3892/ijo.2015.3004 · Cited by 45
Gene Expression Profiles of the NCI-60 Human Tumor Cell Lines Define Molecular Interaction Networks Governing Cell Migration Processes
Kohn, K. W., Zeebèrg, B. R., Reinhold, W. C., Sunshine, M., Luna, A., & Pommier, Y. G. (2012) · PLoS ONE · doi:10.1371/journal.pone.0035716 · Cited by 40
Carvacrol Targets AXL to Inhibit Cell Proliferation and Migration in Non-small Cell Lung Cancer Cells
Jung, C. Y., Kim, S., & Lee, C. (2018) · Anticancer Research · doi:10.21873/anticanres.12219 · Cited by 38
AXL Controls Directed Migration of Mesenchymal Triple-Negative Breast Cancer Cells
Zajac, O., Leclère, R., Nicolas, A., Meseure, D., Marchiò, C., Vincent‐Salomon, A., Roman‐Roman, S., Schoumacher, M., & Dubois, T. (2020) · Cells · doi:10.3390/cells9010247 · Cited by 37
p85β regulates autophagic degradation of AXL to activate oncogenic signaling
Rao, L., Mak, V. C. Y., Zhou, Y., Zhang, D., Li, X., Fung, C. C. Y., Sharma, R., Gu, C., Lu, Y., Tipoe, G. L., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-16061-7 · Cited by 38
Phase 1b study of AVB-500 in combination with paclitaxel or pegylated liposomal doxorubicin platinum-resistant recurrent ovarian cancer
Fuh, K. C., Bookman, M. A., Liu, J. F., Coleman, R. L., Herzog, T. J., Thaker, P. H., Monk, B. J., Anderson, R., McIntyre, G., Rangwala, R. A., et al. (2021) · Gynecologic Oncology · doi:10.1016/j.ygyno.2021.08.020 · Cited by 37
Self-citation
Meta-Analysis of Microarray Data IdentifiesGAS6Expression as an Independent Predictor of Poor Survival in Ovarian Cancer
Buehler, M., Tse, B. W.-C., Leboucq, A., Jacob, F., Caduff, R. F., Fink, D. A., Goldstein, D. R., & Heinzelmann-Schwarz, V. A. (2013) · BioMed Research International · doi:10.1155/2013/238284 · Cited by 37
Soluble AXL: A Possible Circulating Biomarker for Neurofibromatosis Type 1 Related Tumor Burden
Johansson, G., Peng, P.-C., Huang, P.-Y., Chien, H., Hua, K., Kuo, M., Chen, C., & Lee, M. (2014) · PLoS ONE · doi:10.1371/journal.pone.0115916 · Cited by 36
Gene of the month: Axl
Brown, M., Black, J. R., Sharma, R., Stebbing, J., & Pinato, D. J. (2016) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2016-203629 · Cited by 37
The tumour suppressor OPCML promotes AXL inactivation by the phosphatase PTPRG in ovarian cancer
Antony, J., Zanini, E., Kelly, Z., Tan, T. Z., Karali, E., Alomary, M. N., Jung, Y., Nixon, K., Cunnea, P., Fotopoulou, C., et al. (2018) · EMBO Reports · doi:10.15252/embr.201745670 · Cited by 36
Functional roles of enhancer of zeste homolog 2 in gliomas
Yin, Y., Qiu, S., & Peng, Y. (2015) · Gene · doi:10.1016/j.gene.2015.09.080 · Cited by 35
Targeting MERTK and AXL in EGFR Mutant Non-Small Cell Lung Cancer
Yan, D., Earp, H. S., DeRyckere, D., & Graham, D. K. (2021) · Cancers · doi:10.3390/cancers13225639 · Cited by 35
Aptamers as Potential Therapeutic Tools for Ovarian Cancer: Advancements and Challenges
Szymanowski, W., Szymanowska, A., Bielawska, A., Lopez‐Berestein, G., Rodriguez‐Aguayo, C., & Amero, P. (2023) · Cancers · doi:10.3390/cancers15215300 · Cited by 35
Novel Axl-driven signaling pathway and molecular signature characterize high-grade ovarian cancer patients with poor clinical outcome
Rea, K., Pinciroli, P., Sensi, M., Alciato, F., Bisarò, B., Lozneanu, L., Raspagliesi, F., Centritto, F., Cabodi, S., Defilippi, P., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.5087 · Cited by 34
Inhibition of the Receptor Tyrosine Kinase AXL Restores Paclitaxel Chemosensitivity in Uterine Serous Cancer
Palisoul, M. L., Quinn, J. M., Schepers, E. J., Hagemann, I. S., Guo, L., Reger, K., Hagemann, A. R., McCourt, C. K., Thaker, P. H., Powell, M. A., et al. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0587 · Cited by 33
Self-citation
Therapeutic activity of DCC‐2036, a novel tyrosine kinase inhibitor, against triple‐negative breast cancer patient‐derived xenografts by targeting AXL/MET
Shen, Y., Zhang, W., Liu, J., He, J., Cao, R., Chen, X., Peng, X., Xu, H., Zhao, Q., Zhong, J., et al. (2018) · International Journal of Cancer · doi:10.1002/ijc.31915 · Cited by 34
Axl and prostasin are biomarkers for prognosis of ovarian adenocarcinoma
Chen, P., Li, Q., & Yang, Z. (2013) · Annals of Diagnostic Pathology · doi:10.1016/j.anndiagpath.2013.01.005 · Cited by 33
AXL modulates extracellular matrix protein expression and is essential for invasion and metastasis in endometrial cancer
Divine, L. M., Nguyen, M. R., Meller, E. H., Desai, R. A., Arif, B., Rankin, E. B., Bligard, K. H., Meyerson, C., Hagemann, I. S., Massad, M., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.12637 · Cited by 32
Self-citation
Inactivation of GSK3β and activation of NF-κB pathway via Axl represents an important mediator of tumorigenesis in esophageal squamous cell carcinoma
Paccez, J. D., Duncan, K., Vava, A., Correa, R. G., Libermann, T. A., Parker, M. I., & Zerbini, L. F. (2015) · Molecular Biology of the Cell · doi:10.1091/mbc.e14-04-0868 · Cited by 32
Receptor Tyrosine Kinases in Osteosarcoma: Not Just the Usual Suspects
Rettew, A. N., Getty, P. J., & Greenfield, E. M. (2014) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-04843-7_3 · Cited by 30

Authors: Rankin, E. B., Fuh, K. C., Taylor, T. E., Krieg, A. J., Musser, M., Yuan, J., Wei, K., Kuo, C. J., Longacre, T. A., & Giaccia, A. J.
Affiliations: University of Illinois Urbana-Champaign (US)
Corresponding author: Giaccia, Amato J.
ORCID: Rankin, Erinn B.
Fuh, Katherine C.
Taylor, Tiffany E.
Krieg, Adam J.
Wei, Kevin
Kuo, Calvin J.
Longacre, Teri A.
Giaccia, Amato J.
Venue: Cancer Research
Publisher: American Association for Cancer Research (AACR)
Published: 2010-09-29
Volume: 70
Issue: 19
Pages: 7570-7579
ISSN: 0008-5472 (ISSN-L)
1538-7445
DOI: 10.1158/0008-5472.can-10-1267
PMC: PMC3408227
OpenAlex: W2132286757
Cited by: 229
References: 49
Citations by year: 2026: 5 · 2025: 10 · 2024: 16 · 2023: 14 · 2022: 16 · 2021: 18 · 2020: 13 · 2019: 14 · 2018: 18 · 2017: 17 · 2016: 25 · 2015: 20 · 2014: 14 · 2013: 16 · 2012: 6
FWCI: 11.00
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: Cancer Research (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
Funders: National Cancer Institute (CA116685, P01CA067166, T32CA009151, T32CA09151, F32CA124082, CA 67166, R01CA116685, T32CA009302)
National Institute of Diabetes and Digestive and Kidney Diseases (U24DK085532, U01DK085527, U01DK085532)
Topics: Health Sciences › Medicine › Oncology › Ovarian cancer diagnosis and treatment
Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Mechanisms and Therapy
Keywords: AXL receptor tyrosine kinase, metastatic ovarian cancer, therapeutic target, tumor invasion, matrix metalloproteinase activity, metastasis suppression
MeSH terms: Axl Receptor Tyrosine Kinase, Growth Arrest-Specific Protein 6, Adenoviridae, Animals, Female, Humans, Mice, Nude, Neoplasm Metastasis, Ovarian Neoplasms, Plasmids, Proto-Oncogene Proteins, Signal Transduction, Receptor Protein-Tyrosine Kinases, Xenograft Model Antitumor Assays, RNA, Small Interfering, Intercellular Signaling Peptides and Proteins, Cell Line, Tumor, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

AXL Is an Essential Factor and Therapeutic Target for Metastatic Ovarian Cancer

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks